echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > GUT: Anti-SARS-CoV-2 antibody response weakened in patients with IBD treated with infliximab

    GUT: Anti-SARS-CoV-2 antibody response weakened in patients with IBD treated with infliximab

    • Last Update: 2021-03-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Anti-tumor necrosis factor (anti-TNF) drugs damage the protective immunity of pneumococcal, influenza and viral hepatitis vaccines , increasing the risk of severe respiratory infections .


    Immune infection

    They compared the antibody response of participants receiving infliximab with a reference group receiving vedolizumab.


    Forest plot showing the correlation coefficient of the multivariate logistic regression model with anti- SARS-CoV-2 antibody positive

    Forest diagram shows the anti- SARS-CoV-2 multi-variable antibody positive logistic regression correlation coefficient forest illustration shows the anti- SARS-CoV-2 multi-variable antibody positive logistic regression correlation coefficient

    A hierarchical density map of the size of the anti- SARS-CoV-2 antibody reactivity through biological therapy .


    A hierarchical density map of the size of the anti- SARS-CoV-2 antibody reactivity through biological therapy .


    The study found that symptomatic and confirmed SARS-CoV-2 infection rates and hospitalization rates were similar between patients treated with infliximab and vedoliximab, indicating that our findings cannot be based on acquired or severe infections.


    The serological response to SARS-CoV-2 infection in patients receiving infliximab treatment decreased, and the seroprevalence rate, seroconversion rate, and antibody reactivity decreased.


    Patients receiving infliximab treatment have a reduced serological response to SARS-CoV-2 SARS-CoV-2 infection, and reduced seropositivity, seroconversion rate, and antibody reactivity in patients receiving infliximab treatment .


    Kennedy, Nicholas A et al.


    Kennedy, Nicholas A et al.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.